Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Teva UK introduces first biosimilar medicine

Teva UK introduces first biosimilar medicine

4th December 2009

Teva UK has introduced its first-ever biosimilar medicine to pharmacies.

TevaGrastim – a proprietary version of filgrastim – represents a major addition to Teva’s hospital products portfolio and is indicated for a number of treatment areas.

A biosimilar is sometimes referred to as a biogeneric and is defined as a similar biological medicinal product.

TevaGrastim can be used to reduce chemotherapy-induced neutropenia and is available in 30 MIU pre-filled syringes and 48 MIU pre-filled syringes.

The product’s packaging will also feature a needle guard to minimise the risk of accidental injuries among patients.

According to Teva UK, TevaGrastim is a competitively priced3 G-CSF treatment when comparing NHS list prices of filgrastim products.

Teva was established 70 years ago and is focused on several areas, such as generics, respiratory and hospital products.

Among these are Carboplatin, Cisplatin, Doxorubin, Etoposide and Calcium Folinate.

On an international scale, Teva has over 26,000 employees.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.